Drug or treatment

Dinutuximab clinical trials

• 10Clinical trials
• 10Countries

Newest trials

All recruiting trials (10)

• Dinutuximab-beta with chemotherapy in newly diagnosed high-risk neuroblastoma

  This pilot study tests whether adding the antibody dinutuximab-beta to standard induction chemotherapy is safe and helps shrink tumors in kids and young adults with newly diagnosed high-risk neuroblastoma.

  Recruiting at 2 sites Phase 1 Chang Gung Memorial Hospital · Taipei, Taiwan and 1 other locations · NCT07688252

• Iberdomide added to chemoimmunotherapy for relapsed or refractory neuroblastoma

  This study tests whether adding iberdomide to a chemoimmunotherapy regimen helps children and young people with relapsed, refractory, or progressing neuroblastoma.

  Recruiting at 4 sites Phase 1/2 National Cancer Institute (NCI) · Oakland, California and 3 other locations · NCT07437963

• Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for relapsed or refractory neuroblastoma in children

  This trial tests a four-drug combination to see if it can control neuroblastoma in children whose disease has come back or not responded to treatment.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07318831

• rhIL-15 with dinutuximab plus irinotecan and temozolomide for relapsed or refractory neuroblastoma in children and young adults

  This trial will test whether adding rhIL-15 to dinutuximab with irinotecan and temozolomide helps children and young adults (ages 3-35) whose neuroblastoma has returned or not responded to prior treatments.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06995872

• Gudinutuximab Beta Added to Standard Chemo for GD2-Positive Ewing Sarcoma (Early-Phase Trial)

  This early-phase study tests whether adding dinutuximab beta to standard VDC/IE chemotherapy is feasible and safe for patients with GD2-positive high-risk Ewing sarcoma.

  Recruiting at 3 sites Phase 1 German Society for Pediatric Oncology and Hematology GPOH gGmbH · Göttingen, Lower Saxony and 4 other locations · NCT06839703

• Dinutuximab beta combined with two induction chemotherapy regimens for newly diagnosed high-risk neuroblastoma

  This will test different doses of dinutuximab beta given with two standard induction chemotherapy regimens in children (18 months to under 18 years) with newly diagnosed high‑risk neuroblastoma to find a safe recommended dose.

  Recruiting Phase 1 Princess Maxima Center for Pediatric Oncology · Utrecht, Utrecht · NCT06485947

• STING: sequential temozolomide, irinotecan, donor NK cells, and dinutuximab for neuroblastoma

  This will test whether adding donor TGF‑beta‑imprinted NK cells to dinutuximab plus temozolomide, irinotecan, and GM‑CSF helps children and young adults with relapsed or refractory high‑risk neuroblastoma.

  Recruiting at 8 sites Phase 2 New Approaches to Neuroblastoma Therapy Consortium · Los Angeles, California and 12 other locations · NCT06450041

• Combining dinutuximab with chemotherapy and surgery for treating high-risk neuroblastoma in children

  This study is testing if adding a new medicine called dinutuximab to regular chemotherapy and surgery can help children with high-risk neuroblastoma live longer without their cancer coming back.

  Recruiting at 177 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 179 other locations · NCT06172296

• Using expanded gamma delta T cells with chemotherapy for treating relapsed neuroblastoma and osteosarcoma

  This study is testing if a new treatment using special immune cells along with chemotherapy can help children with relapsed neuroblastoma and osteosarcoma feel better and improve their chances of recovery.

  Recruiting Phase 1 Emory University · Atlanta, Georgia · NCT05400603

• Using dinutuximab beta with chemotherapy to treat high-risk neuroblastoma in children

  This study is testing if a new treatment combining dinutuximab beta with chemotherapy can help children with high-risk neuroblastoma who haven't responded to other treatments.

  Recruiting Phase 1 Jagiellonian University · Krakow, Malopolska · NCT05272371

Quick answers

How many clinical trials of Dinutuximab are recruiting right now?

10, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 10 countries. The most sites are in United States (5 trials), Netherlands (1 trial), China (1 trial), Taiwan (1 trial), Australia (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 6, Phase 2: 2, Phase 3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →